; (ii) to permit the Comptroller General to review the information provided; and (iii) to permit the Director of the Congressional Budget Office to review the information provided. . (b) Enforcement (1) In general Section 1847A such Act ( 42 U.S.C. 1395w–3a ) is further amended— (A) in subsection (d)(4)— (i) in subparagraph (A), by striking In general and inserting Misrepresentation ; (ii) in subparagraph (B), by striking subparagraph (B) and inserting subparagraph (A), (B), or (C) ; (iii) by redesignating subparagraph (B) as subparagraph (D); and (iv) by inserting after subparagraph (A) the following new subparagraphs: (B) Failure to provide timely information If the Secretary determines that a manufacturer described in subsection (f)(2) has failed to report on information described in section 1927(b)(3)(A)(iii) with respect to a drug or biological in accordance with such subsection, the Secretary shall apply a civil money penalty in an amount of $25,000 for each day the manufacturer has failed to report such information and such amount shall be paid to the Treasury. (C) False information Any manufacturer required to submit information under subsection (f)(2) that knowingly provides false information is subject to a civil money penalty in an amount not to exceed $100,000 for each item of false information. Such civil money penalties are in addition to other penalties as may be prescribed by law.